Trialant
Platform
  • Home
  • Studies
Other
  • Terms of Service
  • Privacy Policy
  1. Studies

Overview

Key facts that identify this study and show where it stands today.

Description

What the study is about and why it is being run, in the researchers' own words.

Conditions

The medical conditions and diseases this study investigates.

Interventions

The treatments and procedures being evaluated in this study.

Participation

Who can join this study and the criteria used to decide.

Design

How the study is designed and how its participant groups are organized.

Contacts

The people to reach with questions about this study or how to join it.

Locations

Where the study is run and whether each site is currently recruiting.

Collaborators

The organizations and people involved in this study.

Similar Studies

Other registered studies that closely resemble this one.

On this page

  • Overview
  • Description
  • Conditions
  • Interventions
  • Participation
  • Design
  • Contacts
  • Locations
  • Collaborators
  • Similar Studies
Workspace
Home
Studies
  • Terms of Service
    Privacy Policy
    Sign up
    NCT02947685
    • Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
      NCT02491983
      CompletedInterventionalPhase 2Updated Dec 9, 2024
    • Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
      NCT02536742
      CompletedInterventionalPhase 2Updated Aug 26, 2026
    • Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
      NCT03969121
      CompletedInterventionalPhase 3Updated Mar 10, 2023
    • Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
      NCT02028507
      CompletedInterventionalPhase 3Updated Sep 25, 2024
    • A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
      NCT02296801
      CompletedInterventionalPhase 2Updated Jan 13, 2022
    • HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
      NCT03322215
      TerminatedInterventionalPhase 2Updated Mar 8, 2024